2022
THE COMPARATIVE EFFICACY OF INCLISIRAN, PCSK9 INHIBITING MONOCLONAL ANTIBODIES, AND EZETIMIBE FOR THE TREATMENT OF HIGH CHOLESTEROL IN ADULTS WITH OR AT RISK OF ASCVD: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
Campbell C, Desai N, Electricwala B, Stoekenbroek R, Kuang Y, Nevo A, Chang H, Uyei J, Cristino J. THE COMPARATIVE EFFICACY OF INCLISIRAN, PCSK9 INHIBITING MONOCLONAL ANTIBODIES, AND EZETIMIBE FOR THE TREATMENT OF HIGH CHOLESTEROL IN ADULTS WITH OR AT RISK OF ASCVD: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS. Journal Of The American College Of Cardiology 2022, 79: 1551. DOI: 10.1016/s0735-1097(22)02542-6.Peer-Reviewed Original Research
2021
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed Z, Juthani P, Lee M, Desai N. PCSK9 Inhibiting Monoclonal Antibodies. Stroke Revisited 2021, 125-133. DOI: 10.1007/978-981-16-3923-4_11.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Lipid-lowering medicationsSubset of patientsIschemic strokeLower PCSK9Low-density lipoprotein cholesterolConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Monoclonal antibodiesCoenzyme A (HMG-CoA) reductase inhibitorsComponents of dyslipidemiaHigh-intensity statinsStroke risk reductionModifiable risk factorsHealthy lifestyle modificationsLDL-C levelsRisk of strokeStatin-induced myopathyTreatment of hyperlipidemiaA Reductase InhibitorsLifestyle modificationStatin useLipoprotein cholesterolPCSK9 inhibitorsStroke outcome